Want to see HK:2616 full AI Analyst Report?
CStone Pharmaceuticals (2616) Stock Statistics & Valuation Metrics
Total Valuation
CStone Pharmaceuticals has a market cap or net worth of HKD 7.77B. The enterprise value is HKD 5.77B.
- Market Cap
- HKD 7.77B
- Enterprise Value
- HKD 5.77B
Share Statistics
CStone Pharmaceuticals has 1,596,330,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,596,330,900
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
CStone Pharmaceuticals’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -41.59%.
- Return on Equity (ROE)
- -0.71
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -41.59%
- Return on Capital Employed (ROCE)
- -0.51
- Revenue Per Employee
- 1.83M
- Profits Per Employee
- -2.97M
- Employee Count
- 147
- Asset Turnover
- 0.20
- Inventory Turnover
- 1.87
Valuation Ratios
The current PE Ratio of CStone Pharmaceuticals is -15.49. CStone Pharmaceuticals’s PEG ratio is 0.38.
- PE Ratio
- -15.49
- PS Ratio
- 15.79
- PB Ratio
- 4.92
- Price to FCF
- -24.02
- Price to Operating Cash Flow
- -22.92
- PEG Ratio
- 0.38
Income Statement
In the last 12 months, CStone Pharmaceuticals had revenue of 269.58M and earned -437.00M in profits. Earnings per share was -0.31.
- Revenue
- 269.58M
- Gross Profit
- 51.25M
- Operating Income
- -432.62M
- Pretax Income
- -423.94M
- Net Income
- -437.00M
- EBITDA
- -371.84M
- Earnings Per Share (EPS)
- -0.31
Cash Flow
In the last 12 months, operating cash flow was -277.60M and capital expenditures 4, giving a free cash flow of -277.60M billion.
- Operating Cash Flow
- -277.60M
- Free Cash Flow
- -277.60M
- Free Cash Flow per Share
- -0.18
Dividends & Yields
CStone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.16%
- Earnings Yield
- -6.53%
Stock Price Statistics
- Beta
- 1.11
- 52-Week Price Change
- -20.45%
- 50-Day Moving Average
- 5.50
- 200-Day Moving Average
- 6.26
- Relative Strength Index (RSI)
- 46.33
- Average Volume (3m)
- 9.36M
Important Dates
CStone Pharmaceuticals upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
CStone Pharmaceuticals as a current ratio of 2.18, with Debt / Equity ratio of 56.51%
- Current Ratio
- 2.18
- Quick Ratio
- 1.95
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- 1.09
- Interest Coverage Ratio
- -33.46
Taxes
In the past 12 months, CStone Pharmaceuticals has paid 13.06M in taxes.
- Income Tax
- 13.06M
- Effective Tax Rate
- -0.03
Enterprise Valuation
CStone Pharmaceuticals EV to EBITDA ratio is -17.22, with an EV/FCF ratio of -20.28.
- EV to Sales
- 13.33
- EV to EBITDA
- -17.22
- EV to Free Cash Flow
- -20.28
- EV to Operating Cash Flow
- -20.28
Balance Sheet
CStone Pharmaceuticals has HKD 1.56B in cash and marketable securities with HKD 357.17M in debt, giving a net cash position of HKD 1.20B billion.
- Cash & Marketable Securities
- HKD 1.56B
- Total Debt
- HKD 357.17M
- Net Cash
- HKD 1.20B
- Net Cash Per Share
- HKD 0.75
- Tangible Book Value Per Share
- HKD 0.75
Margins
Gross margin is 55.49%, with operating margin of -91.85%, and net profit margin of -98.40%.
- Gross Margin
- 55.49%
- Operating Margin
- -91.85%
- Pretax Margin
- -95.30%
- Net Profit Margin
- -98.40%
- EBITDA Margin
- -77.42%
- EBIT Margin
- -87.87%
Analyst Forecast
The average price target for CStone Pharmaceuticals is HKD 9.65, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- HKD 9.65
- Price Target Upside
- 95.24% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 116.67%
- EPS Growth Forecast
- -0.42%
Scores
- Smart Score
- 1
- AI Score
- 41